RGT — Argent BioPharma Cashflow Statement
0.000.00%
- AU$8.14m
- AU$8.40m
- AU$0.89m
Annual cashflow statement for Argent BioPharma, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.
2020 June 30th | 2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Changes in Working Capital | -3.44 | -3.32 | -4.24 | -1.9 | -2.54 |
Other Operating Cash Flow | |||||
Cash from Operating Activities | -9.96 | -12 | -12.2 | -12 | -14.7 |
Capital Expenditures | -0.962 | -3.33 | -2.69 | -0.19 | -0.14 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | -0.008 | 1.83 | 1.58 | 0.796 | — |
Acquisition of Business | |||||
Sale of Business | |||||
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -0.97 | -1.49 | -1.11 | 0.606 | -0.14 |
Financing Cash Flow Items | -0.788 | -1.2 | -0.703 | -0.102 | -0.437 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 10.5 | 17.1 | 9.74 | 9.73 | 15.3 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -0.481 | 3.56 | -3.55 | -1.65 | 0.463 |